Novel Biomarkers for Early Detection of Hepatocellular Carcinoma
Diagnostics · 13.10.2024 · 14 (20) · 2278
DOI: 10.3390/diagnostics14202278 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 13.10.2024. Verfasst von Abdelrahman M Attia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally. Most patients present with late diagnosis, leading to poor prognosis. This narrative review explores novel biomarkers for early HCC detection. We conducted a comprehensive literature review analyzing protein, circulating nucleic acid, metabolite, and quantitative proteomics-based biomarkers, evaluating the advantages and limitations of each approach. While established markers like alpha-fetoprotein (AFP), des-gamma-carboxy prothrombin, and AFP-L3 remain relevant, promising candidates include circulating tumor DNA, microRNAs, long noncoding RNAs, extracellular vesicle, and metabolomic biomarkers. Multi-biomarker panels like the GALAD score, Oncoguard, and Helio liver test show promise for improved diagnostic accuracy. Non-invasive approaches like urine and gut microbiome analysis are also emerging possibilities. Integrating these novel biomarkers with current screening protocols holds significant potential for earlier HCC detection and improved patient outcomes. Future research should explore multi-biomarker panels, omics technologies, and artificial intelligence to further enhance early HCC diagnosis and management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- Middle East Liver Diseases (MELD) Center, Tehran 1417935840, Iran.
- Department of Internal Medicine, University of Maryland Medical Center, Midtown Campus, Baltimore, MD 21201, USA.
- Department of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- Cedars-Sinai Cancer, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
- Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
ORCID-Profile: Abdelrahman M Attia, Mohammad Saeid Rezaee-Zavareh, Soo Young Hwang, Naomy Kim
Förderung
- NCI NIH HHS
- National Institutes of Health
Zitieren
APA
Attia, A. M., Rezaee-Zavareh, M. S., Hwang, S. Y., Kim, N., Adetyan, H., Yalda, T., Chen, P. J., Koltsova, E. K., & Yang, J. D. (2024). Novel Biomarkers for Early Detection of Hepatocellular Carcinoma. Diagnostics, 14(20), 2278. https://doi.org/10.3390/diagnostics14202278
Vancouver
Attia AM, Rezaee-Zavareh MS, Hwang SY, Kim N, Adetyan H, Yalda T, et al. Novel Biomarkers for Early Detection of Hepatocellular Carcinoma. Diagnostics. 2024;14(20):2278. doi:10.3390/diagnostics14202278
BibTeX
@article{Attia2024,
author = {Attia, Abdelrahman M and Rezaee-Zavareh, Mohammad Saeid and Hwang, Soo Young and Kim, Naomy and Adetyan, Hasmik and Yalda, Tamar and Chen, Pin-Jung and Koltsova, Ekaterina K and Yang, Ju Dong},
title = {Novel Biomarkers for Early Detection of Hepatocellular Carcinoma},
journal = {Diagnostics},
year = {2024},
volume = {14},
number = {20},
pages = {2278},
doi = {10.3390/diagnostics14202278}
}
EUVIMED